ZYDUS LIFESCIENCES LIMITED:

RECEIVES FINAL APPROVAL FROM USFDA FOR DEFLAZACORT ORAL SUSPENSION, 22.75 MG/ML; INDICATED FOR TREATING DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS 5 YEARS AND OLDER; WILL BE PRODUCED AT DOPPEL, ITALY; GROUP NOW HAS 424 APPROVALS AND FILED 487 ANDAS SINCE FY 2003-04.